Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.16 USD

41.16
207,813

-0.02 (-0.05%)

Updated Aug 14, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

by Zacks Equity Research

Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.

GSK or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. NVO: Which Stock Is the Better Value Option?

Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study

by Zacks Equity Research

AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates when Tilray (TLRY) reports first-quarter fiscal 2022 results.

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

by Zacks Equity Research

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More

by Kinjel Shah

Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.

Regeneron (REGN) Reports Positive Data on Antibody Cocktail

by Zacks Equity Research

Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.

J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults

by Zacks Equity Research

J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.

Kinjel Shah headshot

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

by Kinjel Shah

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

Sheraz Mian headshot

Top Research Reports for Microsoft, Amazon & NextEra Energy

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and NextEra Energy, Inc. (NEE).

Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP

by Zacks Equity Research

Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

by Zacks Equity Research

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation

by Zacks Equity Research

Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.

Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries

by Zacks Equity Research

Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.

Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

by Zacks Equity Research

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

by Zacks Equity Research

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

Regeneron, Lilly Get New COVID Drug Deals From Government

by Zacks Equity Research

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

by Zacks Equity Research

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

by Zacks Equity Research

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals

by Zacks Equity Research

AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

by Zacks Equity Research

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.